In an announcement at the International Annual Congress of the World Muscle Society, Amicus Therapeutics showed continuing positive results of their Phase 1/2 clinical study (ATB200-02) to investigate AT-GAA in both ERT-Naive and ERT-Switch patients with Pompe disease. Patients treated with AT-GAA for up to 18 months showed improvements in the six-minute walk test (6MWT) and other measures of motor function and muscle strength, stability or increases in forced vital capacity (FVC), and durable reductions in biomarkers of muscle damage. A very low rare of infusion associated reactions was also noted.
- Sarepta Therapeutics Enters into a Strategic Relationship with Aldevron in Support of Their Gene Therapy Program
- CAP Walks for Muscular Dystrophy in 2018
- Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Study of AT-GAA in Patients with Pompe Disease
- Audentes Therapeutics Pompe Program Update
- Amicus Therapeutics Enters Research and Development Collaboration with University of Pennsylvania to Develop AAV Gene Therapies
advocacy awards Awareness CAP chaperone clinical trials compassion CORD eLearning Emma Rooney ERT Extraordinary Measures Fabry fundraising Gaucher gene therapy getting treated grants guest blogger Int'l Pompe Day IPA late-onset living with Pompe meetings Muscular Dystrophy Canada MyNormal newborn screening Orphan Drug Framework Orphanet politics pre-clinical preclinical pregnancy Rare Disease Rare Disease Day video